AUPH Aurinia Pharmaceuticals Inc

6.01
-0.07  -1%
Previous Close 6.08
Open 6.03
Price To Book 4.14
Market Cap 512912434
Shares 85,343,167
Volume 328,962
Short Ratio
Av. Daily Volume 548,404

NewsSee all news

  1. Aurinia Establishes at-the-Market Facility
  2. Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  3. Aurinia to Participate in November Investor Conferences
  4. Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
  5. Aurinia: 3Q Earnings Snapshot

SEC filingsSee all SEC filings

  1. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181212101
  2. SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] 181212061
  3. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169640
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169602
  5. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181085767

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due January 2019.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 trial initiation announced June 2018. Interim data readouts are anticipated from mid-2019.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 completion of enrollment announced September 25, 2018. Data due 4Q 2019.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. Aurinia Establishes at-the-Market Facility
  2. Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  3. Aurinia to Participate in November Investor Conferences
  4. Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
  5. Aurinia: 3Q Earnings Snapshot
  6. Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
  7. Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
  8. New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS — Factors of Influence, Major Initiatives and Sustained Production
  9. Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September
  10. Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
  11. The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
  12. Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
  13. Aurinia to Participate in Upcoming Investor Conferences
  14. Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
  15. Aurinia Reports Second Quarter Financial Results and Operational Highlights
  16. Aurinia Pharmaceuticals Inc’s (TSE:AUP) Shift From Loss To Profit
  17. Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018

SEC Filings

  1. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181212101
  2. SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] 181212061
  3. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169640
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181169602
  5. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181085767
  6. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181005014
  7. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181004970
  8. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18948761
  9. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18916351
  10. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18914876